Neil Kumar - 10 Feb 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BBIO
Reported as of: 10 Feb 2026
Net transaction value: -$5,748,666
SEC form: 4
Accepted by SEC: 12 Feb 2026, 16:39:55 UTC
Prior SEC filing: 12 Jan 2026
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Will Solis, Attorney-in-Fact

Filing notes and source

Key filing fact

Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 12 Feb 2026.

Key facts

This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
12 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 16:39.

Change

Previous filing in this sequence was filed on 12 Jan 2026.
Current net transaction value: -$5,748,666.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742485 Primary reporting owner

Kumar Neil

Relationship: Chief Executive Officer, Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Will Solis, Attorney-in-Fact
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Sale

Transaction value: $1,019,657
Shares: -14,201
Change %: -2%
Price: $71.80
Shares after: 701,485
Date: 10 Feb 2026
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F2, F3

BBIO transaction

Common Stock

Sale

Transaction value: $419,165
Shares: -5,799
Change %: -0.83%
Price: $72.28
Shares after: 695,686
Date: 10 Feb 2026
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F4

BBIO transaction

Common Stock

Sale

Transaction value: $1,008,006
Shares: -14,040
Change %: -0.31%
Price: $71.80
Shares after: 4,504,407
Date: 10 Feb 2026
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F5

BBIO transaction

Common Stock

Sale

Transaction value: $430,751
Shares: -5,960
Change %: -0.13%
Price: $72.27
Shares after: 4,498,447
Date: 10 Feb 2026
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F6

BBIO transaction

Common Stock

Sale

Transaction value: $551,796
Shares: -7,806
Change %: -1.1%
Price: $70.69
Shares after: 687,880
Date: 11 Feb 2026
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F7

BBIO transaction

Common Stock

Sale

Transaction value: $265,477
Shares: -3,716
Change %: -0.54%
Price: $71.44
Shares after: 684,164
Date: 11 Feb 2026
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F8

BBIO transaction

Common Stock

Sale

Transaction value: $325,695
Shares: -4,484
Change %: -0.66%
Price: $72.64
Shares after: 679,680
Date: 11 Feb 2026
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F9

BBIO transaction

Common Stock

Sale

Transaction value: $292,574
Shares: -3,994
Change %: -0.59%
Price: $73.25
Shares after: 675,686
Date: 11 Feb 2026
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F10

BBIO transaction

Common Stock

Sale

Transaction value: $555,706
Shares: -7,860
Change %: -0.17%
Price: $70.70
Shares after: 4,490,587
Date: 11 Feb 2026
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F7

BBIO transaction

Common Stock

Sale

Transaction value: $269,754
Shares: -3,775
Change %: -0.08%
Price: $71.46
Shares after: 4,486,812
Date: 11 Feb 2026
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F11

BBIO transaction

Common Stock

Sale

Transaction value: $319,938
Shares: -4,404
Change %: -0.1%
Price: $72.65
Shares after: 4,482,408
Date: 11 Feb 2026
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F12

BBIO transaction

Common Stock

Sale

Transaction value: $290,145
Shares: -3,961
Change %: -0.09%
Price: $73.25
Shares after: 4,478,447
Date: 11 Feb 2026
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F13

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 228,776
Date: 10 Feb 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 13 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

Footnote F2

Represents the weighted average sale price of the shares sold from $71.08 to $72.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F3

The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Footnote F4

Represents the weighted average sale price of the shares sold from $72.08 to $72.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F5

Represents the weighted average sale price of the shares sold from $71.02 to $72.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F6

Represents the weighted average sale price of the shares sold from $72.02 to $72.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F7

Represents the weighted average sale price of the shares sold from $70.09 to $71.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F8

Represents the weighted average sale price of the shares sold from $71.09 to $72.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F9

Represents the weighted average sale price of the shares sold from $72.09 to $73.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F10

Represents the weighted average sale price of the shares sold from $73.09 to $73.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F11

Represents the weighted average sale price of the shares sold from $71.1 to $72.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F12

Represents the weighted average sale price of the shares sold from $72.1 to $73.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F13

Represents the weighted average sale price of the shares sold from $73.1 to $73.4 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.